Study reveals cause of common cancer immunotherapy side effect: How checkpoint inhibitors could improve treatments

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint inhibitors experience increased susceptibility to common infections.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup